China's Innovent Biologics said on Monday its GLP-1 injection led to more weight loss and better control of blood sugar in ...

The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk's once-daily oral semaglutide pill to treat people at high risk of ...

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

This article was reviewed by Darragh O’Carroll, MD. Ozempic Alternatives for Weight Loss Key takeaways: Ozempic® alternatives ...

Semaglutide 7 mg and 14 mg tablets are now available for reducing the risk of cardiovascular death, heart attack, or stroke ...

Novo Nordisk announced its oral GLP-1 has been approved by the FDA to reduce risk for major adverse cardiovascular events in ...

GLP-1 injections use needles and require refrigeration. Pills that work in a similar way could be a cheaper, simpler solution.

Novo Nordisk (NVO) has received approval to market its oral GLP-1 medicine Rybelsus in the U.S. to reduce the risk of major ...

About BMF-650 BMF-650 is an investigational, next-generation oral small-molecule GLP-1 RA being developed by Biomea Fusion for the treatment of obesity. Related to the broader orforglipron chemotype, ...

Eli Lilly LLY announced positive top-line data from two late-stage studies evaluating orforglipron, its once-daily oral GLP-1 ...

GLP-1s hold promise as a potential treatment for alcohol and substance use disorders, according to an expert endocrine ...

In a large real-world Italian cohort, GLP-1 receptor agonist therapy led to measurable rates of type 2 diabetes remission, ...